1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Sanofi Matches, But Does Not Better, Amgen In OX40 Contest

 
• By Elizabeth Cairns

Mid-stage data on amlitelimab in uncontrolled atopic dermatitis look in line with rival rocatinlimab, which is already more advanced.      

Businessman and businesswoman armwrestling at the office table, maintaining eye contact, trying to get leadership, fighting for equal rights for women, business competitors in the marketplace

Sanofi has previously stated that amlitelimab could be both a first- and a best-in-class therapy in atopic dermatitis (Also see "Sanofi Looks To Build On Dupixent Dominance With OX40L Drug" - Scrip, 27 June, 2023.). Updated data from a Phase IIb trial released last week, however, suggest that it is doubtful that either goal will be achieved by the anti-OX40-ligand antibody.

Key Takeaways
  • Phase IIb data on Sanofi’s anti-OX40-ligand antibody amlitelimab are good enough to start Phase III
  • But Amgen’s similar product rocatinlimab looks as good or slightly better
  • And rocatinlimab is already years into its

For a start, the product has not yet entered Phase III trials, whereas Amgen, Inc.’s rocatinlimab, a similarly-acting agent licensed from Kyowa Kirin Co., Ltd., is in no fewer than seven in this disease

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.